McGill Centre for Translational Research in Cancer (MCTRC)
The great challenge faced by the oncology research community is in the translation of laboratory and clinical research data into clinical outcomes of benefit in the assessment, treatment and prevention of cancer. The McGill Centre for Translational Research in Cancer (MCTRC) was established thanks to a generous endowment gift from the Goldfarb Family Foundation and the Alexander Family Foundation, and was formally recognized by the McGill University Senate in 1996. Subsequent significant support included an endowment gift from the Montreal Breast Cancer Foundation. A 1997 article in the McGill Reporter outlines the origins of the MCTRC (MCTRC McGill Reporter1997 [pdf]) and in 2001 the Journal of the National Cancer Institute highlighted novel infrastructure (JNCI 93:1373-1374). Since its early years it has established a strong funding and publication record, with an outstanding track record in novel cancer diagnostics and therapeutics.
Based at the Segal Cancer Centre / Lady Davis Research Institute of the Jewish General Hospital, the Centre provides the infrastructure and focus of purpose to bring key investigators involved in translational research together to generate novel approaches to cancer prevention, diagnosis and treatment. From its inception it was designed to be multidisciplinary, multi-institutional and to include clinical and fundamental scientists from across Quebec. The Centre’s main focus is on innovation, new knowledge generation and rapid translation of discoveries from lab to clinic.
The MCTRC team of researchers have access to different Core Facilities equipped with state of the art technologies that allow the development of significant discoveries in the different aspects of cancer research. The MCTRC scientist and clinicians are grouped in six research themes, covering a large spectrum, from biochemistry & drug design to immunotherapies & translational proteomics and artificial intelligence & computer science applied to diagnostic methods. The MCTRC is positioned to contribute to the rapid expansion and deepening of translational cancer research taking place. We are leveraging a variety of potential synergies and creating new partnerships with government, biotech and pharma in order to bring scientific discoveries to patients and to the society.